Cargando…

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE

AIMS: To undertake a post‐hoc analysis, utilizing a hypoglycaemia risk score based on DEVOTE trial data, to investigate if a high risk of severe hypoglycaemia was associated with an increased risk of cardiovascular events, and whether reduced rates of severe hypoglycaemia in patients identified as h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heller, Simon, Lingvay, Ildiko, Marso, Steven P., Philis‐Tsimikas, Athena, Pieber, Thomas R., Poulter, Neil R., Pratley, Richard E., Hachmann‐Nielsen, Elise, Kvist, Kajsa, Lange, Martin, Moses, Alan C., Andresen, Marie Trock, Buse, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754351/ https://www.ncbi.nlm.nih.gov/pubmed/32250536 http://dx.doi.org/10.1111/dom.14049

Ejemplares similares

Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020)

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
por: Zinman, Bernard, et al.
Publicado: (2017)

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
por: Pieber, Thomas R., et al.
Publicado: (2017)

Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE
por: Klein, Klara R, et al.
Publicado: (2021)

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
por: Pratley, Richard E., et al.
Publicado: (2019)

Abstract 4: Derived time-in-range is associated with major adverse cardiovascular event in T2D: Data from the DEVOTE trial
por: Pathan, Muzammil Khan A, et al.
Publicado: (2022)

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
por: Brown‐Frandsen, Kirstine, et al.
Publicado: (2019)

Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE
por: Bergenstal, Richard M., et al.
Publicado: (2023)

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
por: Pratley, Richard E., et al.
Publicado: (2019)

Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials
por: DeVries, J. Hans, et al.
Publicado: (2018)

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2020)

Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)
por: Amod, Aslam, et al.
Publicado: (2020)

The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2020)

Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)
por: Amod, Aslam, et al.
Publicado: (2019)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
por: Pollock, Richard F., et al.
Publicado: (2019)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)
por: Pollock, Richard F., et al.
Publicado: (2019)

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes
por: Philis-Tsimikas, Athena
Publicado: (2008)

Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2022)

100 years on: the impact of the discovery of insulin on clinical outcomes
por: Buse, John B, et al.
Publicado: (2021)

Periodic Intensive Insulin Therapy Remains Experimental
por: Chang, Amy, et al.
Publicado: (2019)

Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials
por: Rose, Ludger, et al.
Publicado: (2019)

Devotion
por: McLaughlin, John, 1942-
Publicado: (1992)

Digital health tools to promote diabetes education and management of cardiovascular risk factors among under-resourced populations
por: Paul, Tenes, et al.
Publicado: (2021)

Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial
por: Pieber, Thomas R., et al.
Publicado: (2021)

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials
por: Kahkoska, Anna R., et al.
Publicado: (2020)

Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes
por: Buse, John B., et al.
Publicado: (2021)

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
por: Pollock, Richard F., et al.
Publicado: (2018)

Devotion to Duty
Publicado: (1906)

Predictors of Dropouts From a San Diego Diabetes Program: A Case Control Study
por: Benoit, Stephen R., et al.
Publicado: (2004)

Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study
por: Benoit, Stephen R, et al.
Publicado: (2005)

Devotion for newborn children
por: Purcarea, VL
Publicado: (2016)

Reducing the burden of hypoglycaemia in people with diabetes through increased understanding: design of the Hypoglycaemia REdefining SOLutions for better liVEs (Hypo‐RESOLVE) project
por: de Galan, B. E., et al.
Publicado: (2020)

Devotions upon emergent occasions
Publicado: (1977)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

The role of structured education in the management of hypoglycaemia
por: Iqbal, Ahmed, et al.
Publicado: (2017)

Improving Treatment of Depression Among Latinos With Diabetes Using Project Dulce and IMPACT
por: Gilmer, Todd P., et al.
Publicado: (2008)

Peer-Led Diabetes Education Programs in High-Risk Mexican Americans Improve Glycemic Control Compared With Standard Approaches: A Project Dulce promotora randomized trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2011)

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)
por: Philis-Tsimikas, Athena, et al.
Publicado: (2013)

The Ordinary Devoted Mother and Her Baby
Publicado: (1950)

Cannot write session to /tmp/vufind_sessions/sess_a5fuukb90hc69o0du10qe73bkg